A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

This study is testing whether adding an immunotherapy drug called adebrelimab — with or without a blood vessel–blocking drug (bevacizumab) — to standard chemotherapy before surgery helps shrink tumors more effectively in people with resectable non-squamous non-small cell lung cancer (a common type of lung cancer that can be surgically removed). **You may be eligible if...** - You are between 18 and 65 years old - You have non-squamous NSCLC that is suitable for surgery - You have not yet received any treatment for this cancer (surgery, chemo, radiation, or biologics) - You are in good general health (ECOG 0–1) with adequate lung function **You may NOT be eligible if...** - You have squamous cell lung cancer or small cell lung cancer - You have previously used immunotherapy (anti-PD1, anti-PDL1, anti-CTLA4) or anti-angiogenic drugs - You have a known allergy to the study drugs - You have severe uncontrolled health conditions Talk to your doctor to see if this trial is right for you.